US › Healthcare

Aura Biosciences Inc (AURA)

US · Healthcare · Biotechnology

$7.15+1.56%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-33.7M
Profit YoY
-22.6%
EPS
$-0.50
EPS estimate
$-0.52

EPS came in at -0.50 against a street estimate of -0.52 — a beat of 3.8%.

Key statistics

Market cap
$728.2M
Forward P/E
0.0
P/B
6.77
Book value
$1.67
EPS (TTM)
$-1.71
52-week high
$9.54
52-week low
$4.73
50-day MA
$6.96
200-day MA
$6.37
Beta
0.40

Analyst view

Analysts rate Aura Biosciences Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $18.80.

Shareholding

Insiders
1.16%
Institutions
49.29%

Largest institutional holders

FundStake
Matrix Capital Management Company, LLC6.69%
Frazier Life Sciences Management, L.P.4.93%
Adage Capital Partners Gp LLC4.72%
Long Focus Capital Management, LLC4.47%
Suvretta Capital Management, LLC4.23%
BlackRock Inc3.47%
Medicxi Ventures Management (Jersey) Ltd2.94%
Vanguard Capital Management, LLC2.17%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aura Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.